Pay in 4 interest-free payments of $6.07 Learn more
Ships within 48 hours · Estimated delivery Sep 29 - Oct 4
MBX 4291, dual GLP-1/GIP co-agonist prodrug designed for potential once-monthly dosing and improved tolerability in obesity Recent Highlights: In June 2026, MBX Biosciences announced data that demonstrated sustained benefit of its once-weekly Canvuparatide as a potential PTH replacement therapy in chronic hypoparathyroidism
rinse well with water
cytokine and chemokine levels propose that the studied combination induces an immune response by altering the host immune defenses (148)
The FDA clarified in an April 2026 notice that these compound drugs can still be considered copies, and are thus illegal
US$ 22.24
US$ 24.80
US$ 20.45
US$ 20.30
